ALLMedicine™ Cardiovascular Risk Reduction Center
Research & Reviews 845 results
https://doi.org/10.1161/JAHA.120.016835
Journal of the American Heart Association; Nelson AJ, Ardissino M et. al.
Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...
https://doi.org/10.1097/MOL.0000000000000724
Current Opinion in Lipidology FURTHER RECOMMENDED READING; Tietge UJF
Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|
https://doi.org/10.1097/MED.0000000000000595
Current Opinion in Endocrinology, Diabetes, and Obesity; Gallo A, Perregaux J et. al.
Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...
https://doi.org/10.1016/S2213-8587(20)30368-5
The Lancet. Diabetes & Endocrinology; Aroda VR, Sabatine MS
Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|
https://doi.org/10.1016/j.jacc.2020.09.004
Journal of the American College of Cardiology; Januzzi JL, Xu J et. al.
Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...
Guidelines 55 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.
Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...
http://www.onlinejacc.org/content/early/2019/03/07/j.jacc.2019.03.010
Journal of the American College of Cardiology;
Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext
Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...
https://jamanetwork.com/journals/jama/article-abstract/2721178
Zheng,S.,et al
Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...
https://www.healio.com/cardiology/chd-prevention/news/online/%7B51d6ca5b-5a70-4e7e-ae7b-84b411d0fd62%7D/evidence-of-cv-benefits-of-mediterranean-diet-growing
Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...
Drugs 3 results see all →
Clinicaltrials.gov 937 results
https://doi.org/10.1161/JAHA.120.016835
Journal of the American Heart Association; Nelson AJ, Ardissino M et. al.
Jan 12th, 2021 - Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmac...
https://doi.org/10.1097/MOL.0000000000000724
Current Opinion in Lipidology FURTHER RECOMMENDED READING; Tietge UJF
Dec 28th, 2020 - Triglycerides as target of cardiovascular risk reduction.|2020|Tietge UJF,|
https://doi.org/10.1097/MED.0000000000000595
Current Opinion in Endocrinology, Diabetes, and Obesity; Gallo A, Perregaux J et. al.
Dec 5th, 2020 - Statins are highly effective therapies for reducing low-density lipoprotein cholesterol and preventing cardiovascular events. However, many patients taking statins experience statin-associated muscle symptoms. In the current manuscript, we review ...
https://doi.org/10.1016/S2213-8587(20)30368-5
The Lancet. Diabetes & Endocrinology; Aroda VR, Sabatine MS
Nov 20th, 2020 - EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.|2020|Aroda VR,Sabatine MS,|
https://doi.org/10.1016/j.jacc.2020.09.004
Journal of the American College of Cardiology; Januzzi JL, Xu J et. al.
Oct 30th, 2020 - Canagliflozin reduces cardiovascular events including hospitalization for heart failure (HHF) in patients with type 2 diabetes and cardiovascular risk. Elevated amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associate...
News 93 results
https://www.medscape.com/viewarticle/937947
Oct 11th, 2020 - Multiple clinical trials demonstrate the efficacy of sodium-glucose co-transporter-2 (SGLT-2) inhibitors to reduce cardiovascular events in persons with diabetes.[1,2,3,4] Use of these agents has been associated with consistent reductions in the c...
https://www.medscape.com/viewarticle/924308
Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...
https://www.staging.medscape.com/viewarticle/922865
Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...
https://www.medscape.com/viewarticle/922865
Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...
https://www.mdedge.com/emergencymedicine/article/214314/lipid-disorders/icosapent-ethyl-approved-cardiovascular-risk?channel=39313
Catherine Hackett
Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.